Clinical trials: Transmission
Cytomegalovirus Infections, Cytomegalovirus Retinitis
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections
- Trial name
- NCT00002025
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease…
- Trial name
- NCT00976950
- Testing
- Tipranavir, ritonavir
- Where
- 20 sites in Romania
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients
To evaluate safety and immune response in HIV-infected patients treated with multiple injections of APL 400-003 vaccine. PER 2/27/96 AMENDMENT: To evaluate the safety of the vaccine when administered via the Biojector 2000…
- Trial name
- NCT00002350
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Apollon
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gonorrhea, Chlamydia
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States.
- Conditions
- Gonorrhea, Chlamydia, Meningococcal Vaccines
- Trial name
- NCT05873751
- Testing
- Trumenba Vaccine, MenACWY Vaccine
- Where
- United States
- Volunteers
- 1,307,378 people
- Sponsor
- Pfizer
HIV Infections
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
- Trial name
- NCT00002369
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Condylomata Acuminata, Papillomavirus Infections
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious
- Trial name
- CARE-1 (NCT03981822)
- Testing
- VP-102 and applicator
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Genital Warts, Perianal Warts
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations…
- Trial name
- NCT01082302
- Testing
- Polyphenon E (Veregen) 15% ointment, Green Tea Beverage with defined catechin content
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- MediGene
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)
This is an open-label, single-sequence, two-way drug interaction study to investigate the PK, safety and tolerability of GSK3640254 and DTG when administered alone or in combination in healthy subjects.
- Trial name
- NCT03816696
- Testing
- GSK3640254, DTG
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
HIV Infection, Infection, Human Immunodeficiency Virus
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body.
- Trial name
- NCT00386347
- Testing
- GSK364735 oral solution and oral tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Candidiasis, Mycoses
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal…
- Conditions
- Candidiasis, Mycoses, HIV Infections
- Trial name
- NCT00002038
- Testing
- Fluconazole
- Where
- United States
- Sponsor
- Pfizer
HIV Infections
Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
The objectives of this study are to explore the metabolic toxicities associated with lopinavir/ritonavir (LPV/r) plus saquinavir mesylate (INV) versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the overall…
- Trial name
- NCT00043953
- Testing
- Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Abbott
HIV Infection
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir).
- Trial name
- NCT00435838
- Testing
- No Intervention -- Observational study
- Where
- 25 sites in Austria, Belgium and 5 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
HIV Infections
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of antiretrovirals in patients with HIV infection.
- Trial name
- NCT00002347
- Testing
- Saquinavir, Nevirapine, Zidovudine
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Parexel
HIV Infections, Fanconi Syndrome
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
Cross-sectional cohort study of participants with HIV with or without protocol-defined Fanconi syndrome (confirmed creatinine clearance [CLcr] decline and evidence of proximal tubulopathy).
- Conditions
- HIV Infections, Fanconi Syndrome, Kidney Disease, Renal Impairment
- Trial name
- NCT00499187
- Testing
- Blood Draws
- Where
- 13 sites in United States, Canada
- Volunteers
- 56 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given subcutaneously in conjunction with antiviral treatment and to explore the effects of treatment on surrogate markers of efficacy and incidence of…
- Trial name
- NCT00001997
- Testing
- Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections, Chickenpox
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
- Trial name
- NCT00002358
- Testing
- Sorivudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Chlamydia Trachomatis Immunization
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.